Dwayne C. Jones

Array ( [id] => 19041648 [patent_doc_number] => RE049873 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2024-03-19 [patent_title] => APP specific bace inhibitors (ASBIs) and uses thereof [patent_app_type] => reissue [patent_app_number] => 17/382969 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 34708 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19074674 [patent_doc_number] => RE049897 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2024-04-02 [patent_title] => Salts of a dihydroquinazoline derivative [patent_app_type] => reissue [patent_app_number] => 17/320587 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6564 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18946501 [patent_doc_number] => RE049825 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2024-02-06 [patent_title] => Piperidinyl nociceptin receptor compounds [patent_app_type] => reissue [patent_app_number] => 17/245700 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38839 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18699385 [patent_doc_number] => RE049698 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2023-10-17 [patent_title] => Substituted dihydroquinazolines [patent_app_type] => reissue [patent_app_number] => 16/934363 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13865 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 220 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18930375 [patent_doc_number] => RE049816 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2024-01-30 [patent_title] => Dipeptides as inhibitors of human immunoproteasomes [patent_app_type] => reissue [patent_app_number] => 16/893086 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 34973 [patent_no_of_claims] => 76 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16893086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993169 [patent_doc_number] => 20200172455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => PROCESSES FOR THE PRODUCTION OF FLUOROPROPANES AND HALOPROPENES [patent_app_type] => utility [patent_app_number] => 16/781025 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16781025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070014 [patent_doc_number] => RE049338 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-12-20 [patent_title] => Phthalazinone derivatives and manufacturing process thereof [patent_app_type] => reissue [patent_app_number] => 16/447174 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34502 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16447174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17996077 [patent_doc_number] => RE049302 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2022-11-15 [patent_title] => Pharmaceutical formulations containing dopamine receptor ligands [patent_app_type] => reissue [patent_app_number] => 16/384264 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12207 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384264 [rel_patent_id] =>[rel_patent_doc_number] =>)